Genentech

Genentech

Biotechnology company that discovers, develops, manufactures and commercializes therapeutic products for serious or life-threatening medical conditions. Disease areas include oncology, immunology, ophthalmology, metabolism and virology. Genentech has been a member of the Roche Group since 2009.

In 2009 Genentech became a member of the Roche Group and the two companies combined their pharmaceutical operations in the US. The San Francisco campus of Genentech serves as headquarters for Roche pharmaceutical operations in the US. Operating as an independent center within Roche is Genentech Research and Early Development.

Genentech was founded by Robert A. Swanson (1947-1999), a venture capitalist, and biochemist Dr. Herbert W. Boyer. Boyer along with Stanley Cohen were pioneers in recombinant DNA technology.

Genetech has drug manufacturing facilities in South San Francisco, Vacaville and Oceanside, California. Genetech focused on large-scale biologics and products for about 30 years. A shift towards developing therapies that target smaller patient populations began around 2013. Genentech has two commercial large volume products, Herceptin and Rituxan, of which they produce more than 2000 kg per year. The company has six products that classify as standard volume products, between 300 kg and 2000 kg per year, as well as three in clinical trials. As of 2019 Genetech had four products considered small volume, less than 300 kg per year, and nine small volume products in the pipeline.

Genentech is developing a virtual reality simulator for eye surgery.

Products

Biooncology

Alecensa® (alectinib)

Avastin® (bevacizumab)

Cotellic® (cobimetinib)

Erivedge® (vismodegib)

Gazyva® (obinutuzumab)

Herceptin® (trastuzumab)

Herceptin Hylecta™ (trastuzumab and hyaluronidase-oysk)

Kadcyla® (ado-trastuzumab emtansine)

Perjeta® (pertuzumab)

Rituxan® (rituximab [Oncology])

Rituxan Hycela™ (rituximab and hyaluronidase human)

Tarceva® (erlotinib)

Tecentriq® (atezolizumab)

Venclexta® (venetoclax)

Xeloda® (capecitabine)

Zelboraf® (vemurafenib)

Immunology and Ophthalmology

Actemra® (tocilizumab)

Esbriet® (pirfenidone)

Lucentis™ (ranibizumab injection)

Rituxan® (rituximab [Immunology])

Xolair® (omalizumab)

Metabolism and Primary Care

Activase® (alteplase)

Cathflo Activase® (alteplase)

Nutropin AQ® (somatropin (rDNA origin) for injection)

TNKase® (tenecteplase)

Neurology

Ocrevus® (ocrelizumab)

Virology and Specialty Care

CellCept® (mycophenolate mofetil)

Pegasys® (peginterferon alfa-2a)

Pulmozyme® (dornase alfa)

Tamiflu® (oseltamivir phosphate)

Valcyte® (valganciclovir hydrochloride)

Xofluza ™ (baloxavir marboxil)

Other

Boniva Injection® (ibandronate sodium)

Boniva Tablets® (ibandronate sodium)

Cytovene® (ganciclovir)

Fuzeon® (enfuvirtide)

Hemlibra® (emicizumab-kxwh)

Invirase® (saquinavir mesylate)

Klonopin® (clonazepam)

Valium® (diazepam)

Timeline

People

Name
Role
LinkedIn

aakanksha patel

Employee

Aaron Yip

Employee

Aashima Singhal

Founder

Abraham Gacad

Employee

Adam Tomashek

Employee

Adhithya Mohanraj

Employee

Adilet Matkerimov

Employee

Adrian Jubb

Employee

Adriana Delor

Employee

Ajay Kshatriya

Employee

AKASH ARYA

Employee

Akila Gopalakrishnan

Employee

Akila Subramanian

Employee

Akiyo Marukawa

Previous Employee

Alan C Pikna

Employee

Alan Pruitt

Employee

Alec Howard

Employee

Alefiyah Shambhoora

Employee

Alekhya Akkunuri

Employee

Alex Bash

Employee

Alex Fischer

Employee

Alex Pomerantz

Employee

Alex Smoligovets

Employee

Alexander Kislukhin

Employee

Alexander Kozintsev

Employee

Page 1 of 27

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
BioSpace
May 28, 2020
BioSpace
Genentech is also close to completing enrollment of a global randomized, double-blind, placebo-controlled Phase III clinical trial of Actemra in hospitalized patients with severe COVID-19 pneumonia (COVACTA), with results expected this summer
Krystle Vermes
May 27, 2020
BioSpace
Genentech announced on Wednesday that it has seen positive topline results from Archway, its Phase III study looking into its Port Delivery System (PDS) with ranibizumab for the treatment of neovascular or "wet" age-related macular degeneration.
Alex Keown
May 27, 2020
BioSpace
Since COVID-19 began its sweep across the United States, data has shown the disease caused by the novel coronavirus has disproportionately impacted racial and ethnic minority groups across the country.
BioSpace
May 22, 2020
BioSpace
Pooled data from two pivotal Phase III open-label extension (OLE) studies show satralizumab was well-tolerated as a monotherapy or in combination with baseline immunosuppressive therapy in people with neuromyelitis optica spectrum disorder (NMOSD)
May 18, 2020
BioSpace
Flatiron Health, Foundation Medicine and Genentech Partner to Launch Novel Prospective Lung Cancer Clinical Study - read this article along with other careers information, tips and advice on BioSpace
Mark Terry
May 14, 2020
BioSpace
Genentech, a Roche company, announced positive results from the Phase II CITYSCAPE clinical trial in PD-L1-positive metastatic non-small cell lung cancer.
Nick Paul
May 11, 2020
FierceBiotech
Roche has named Aviv Regev as the new head of Genentech research and early development (gRED). Regev, who currently works at the Broad Institute, will take over as head of gRED when Michael Varney retires at the end of July.
April 2, 2020
WebWire
Pfizer Inc. (NYSE: PFE) today announced the election of Dr. Susan Desmond-Hellmann to its Board of Directors, effective immediately. Dr. Desmond-Hellmann, age 62, was also appointed to the Governance & Sustainability Committee and the Science and Technology Committee of Pfizer's Board. Dr. Desmond-Hellmann served as Chief Executive Officer of the Bill & Melinda Gates Foundation from 2014 until 2020, where she oversaw the creation of the Gates Medical Research Institute--the world's first n...
Bob Violino
January 13, 2020
InsiderPro
The enterprise architect role has emerged as one of the most pivotal in IT, especially for companies in the midst of a digital transformation. Here's a look at what it takes to become an enterprise architect.
David Riggs
September 17, 2019
TechCrunch
We face two major threats today: one to the health of our planet and the other to our own. Fortunately, biology and technology are creating fixes for the planet as well as for the human body.
October 20, 2018
nytimes.com
Combining immunotherapy and chemotherapy can help women with an aggressive type of breast cancer and should become their new standard of care.

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.